As an antigen highly expressed on multiple myeloma cells, CD38 serves as a target for commercially available monoclonal antibodies that can be used in either the first-line setting or in the R/R setting with well-documented clinical efficacy [52,53]. This evidence concerns the gene CD38 and plasma cell myeloma.